Finance entity
earnings is the sole category represented across all 1 tracked stories. Beta Bionics, Inc. is most often covered alongside Nasdaq, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.7 in the same window.
Last mentioned: Feb 18, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. Beta Bionics, Inc. is most often covered alongside Nasdaq, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.7 in the same window. Each story carries 3 original sources on average, compared with 4.7 for the broader beat in this window. Beta Bionics, Inc. appears in 1 tracked Finance story from February 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 90 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Beta Bionics, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Beta Bionics and NeoGenomics posted strong Q4 2025 results driven by automated insulin delivery and oncology diagnostics, respectively. Meanwhile, SSR Mining focused on operational stabilization and cost discipline following a volatile fiscal year for precious metals.
Beta Bionics, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
